Acute Myeloid Leukemia Clinical Trial
Alvocidib Biomarker-driven Phase 2 AML Study
The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM (Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML patients with demonstrated MCL-1 dependence of â‰¥ 30% by mitochondrial profiling in bone marrow.
In Stage 1 of the study, all eligible AML patients with demonstrated MCL-1 dependence of ≥ 30% by mitochondrial profiling in bone marrow will receive treatment with ACM.
In Stage 2, all eligible AML patients with demonstrated MCL-1 dependence of ≥ 30% by mitochondrial profiling in bone marrow will be randomized 1:1 to receive either treatment with ACM or CM.
Be between the ages of ≥18 and ≤65 years
Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M3) with a bone marrow of >5% blasts based on histology or flow cytometry
Be in first relapse (within 24 months of CR) or have failed induction therapy* (no CR or CRi after treatment with an intensive regimen (eg, anthracycline/cytarabine ± etoposide, gemtuzumab ozogamicin, or cladribine).
*Induction therapy may involve 1 or 2 cycles of the same regimen. Efficacy assessment of induction therapy must be >21 days from the start of the previous induction cycle.
Demonstrate MCL-1 dependence of ≥30% by mitochondrial profiling in bone marrow.
Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2
Have a serum creatinine level ≤1.8 mg/dL
Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ≤5 times upper limit of normal (ULN)
Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)
Have a left ventricular ejection fraction (LVEF) >45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate during and for at least 6 months after completion of study therapy.
Be able to comply with the requirements of the entire study.
Provide written informed consent prior to any study related procedure.
Received more than 2 cycles of induction therapy for AML. Investigational agents as part of front-line therapy for AML may by acceptable following discussion with the Medical Monitor. Hydroxyurea is permitted (see #5 below).
Received any previous treatment with alvocidib or any other CDK inhibitor
Received a hematopoietic stem cell transplant within the previous 2 months
Have clinically significant graft versus host disease (GVHD), or GVHD requiring initiation or escalation of treatment within the last 21 days
Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm.
Received >360 mg/m2 equivalents of daunorubicin
Have a peripheral blast count of >30,000/mm3 (may use hydroxyurea as in #5 above)
Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor.
Diagnosed with acute promyelocytic leukemia (APL, M3)
Have active central nervous system (CNS) leukemia
Have evidence of uncontrolled disseminated intravascular coagulation
Have an active, uncontrolled infection
Have other life-threatening illness
Have other active malignancies or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia
Have mental deficits and/or psychiatric history that may compromise the ability to give written informed consent or to comply with the study protocol.
Are pregnant and/or nursing
Have received any live vaccine within 14 days prior to first study drug administration.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 33 Locations for this study
Scottsdale Arizona, 85258, United States
Los Angeles California, 90095, United States
San Diego California, 92093, United States
Jacksonville Florida, 32224, United States
Atlanta Georgia, 30342, United States
Chicago Illinois, 60611, United States
Iowa City Iowa, 52242, United States
Westwood Kansas, 66205, United States
New Orleans Louisiana, 70121, United States
Baltimore Maryland, 21287, United States
Ann Arbor Michigan, 48109, United States
Rochester Minnesota, 55905, United States
Omaha Nebraska, 68198, United States
Morristown New Jersey, 07960, United States
Buffalo New York, 14263, United States
Hawthorne New York, 10532, United States
New York New York, 10032, United States
Chapel Hill North Carolina, 27599, United States
Durham North Carolina, 27710, United States
Greenville North Carolina, 27858, United States
Cleveland Ohio, 44195, United States
Columbus Ohio, 43210, United States
Pittsburgh Pennsylvania, 15224, United States
Dallas Texas, 75246, United States
Houston Texas, 77030, United States
Milwaukee Wisconsin, 53226, United States
Toronto Ontario, M5G 2, Canada
Málaga Malaga, 29010, Spain
Albacete , 02006, Spain
Badalona , , Spain
Barcelona , 08036, Spain
Cáceres , , Spain
Oviedo , 33011, Spain
Salamanca , 37007, Spain
Valencia , , Spain
Cardiff Wales, CF10 , United Kingdom
Bristol , , United Kingdom
London , , United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.